PCRX
Price
$25.24
Change
-$0.41 (-1.60%)
Updated
Sep 26 closing price
Capitalization
1.13B
32 days until earnings call
TEVA
Price
$18.34
Change
-$0.02 (-0.11%)
Updated
Sep 26 closing price
Capitalization
21.69B
39 days until earnings call
Interact to see
Advertisement

PCRX vs TEVA

Header iconPCRX vs TEVA Comparison
Open Charts PCRX vs TEVABanner chart's image
Pacira BioSciences
Price$25.24
Change-$0.41 (-1.60%)
Volume$474.41K
Capitalization1.13B
Teva Pharmaceutical Industries
Price$18.34
Change-$0.02 (-0.11%)
Volume$10.26M
Capitalization21.69B
PCRX vs TEVA Comparison Chart in %
Loading...
PCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TEVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PCRX vs. TEVA commentary
Sep 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PCRX is a Hold and TEVA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 28, 2025
Stock price -- (PCRX: $25.24 vs. TEVA: $18.34)
Brand notoriety: PCRX: Not notable vs. TEVA: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: PCRX: 68% vs. TEVA: 89%
Market capitalization -- PCRX: $1.13B vs. TEVA: $21.69B
PCRX [@Pharmaceuticals: Generic] is valued at $1.13B. TEVA’s [@Pharmaceuticals: Generic] market capitalization is $21.69B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PCRX’s FA Score shows that 0 FA rating(s) are green whileTEVA’s FA Score has 1 green FA rating(s).

  • PCRX’s FA Score: 0 green, 5 red.
  • TEVA’s FA Score: 1 green, 4 red.
According to our system of comparison, TEVA is a better buy in the long-term than PCRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PCRX’s TA Score shows that 4 TA indicator(s) are bullish while TEVA’s TA Score has 4 bullish TA indicator(s).

  • PCRX’s TA Score: 4 bullish, 4 bearish.
  • TEVA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, PCRX is a better buy in the short-term than TEVA.

Price Growth

PCRX (@Pharmaceuticals: Generic) experienced а -5.33% price change this week, while TEVA (@Pharmaceuticals: Generic) price change was -0.05% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.16%. For the same industry, the average monthly price growth was +24.25%, and the average quarterly price growth was +66.99%.

Reported Earning Dates

PCRX is expected to report earnings on Oct 30, 2025.

TEVA is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.16% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TEVA($21.7B) has a higher market cap than PCRX($1.13B). PCRX YTD gains are higher at: 33.970 vs. TEVA (-16.788). TEVA has higher annual earnings (EBITDA): 1.9B vs. PCRX (-1.3M). TEVA has more cash in the bank: 2.16B vs. PCRX (446M). PCRX has less debt than TEVA: PCRX (631M) vs TEVA (17.5B). TEVA has higher revenues than PCRX: TEVA (16.6B) vs PCRX (706M).
PCRXTEVAPCRX / TEVA
Capitalization1.13B21.7B5%
EBITDA-1.3M1.9B-0%
Gain YTD33.970-16.788-202%
P/E Ratio13.04N/A-
Revenue706M16.6B4%
Total Cash446M2.16B21%
Total Debt631M17.5B4%
FUNDAMENTALS RATINGS
PCRX vs TEVA: Fundamental Ratings
PCRX
TEVA
OUTLOOK RATING
1..100
7283
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
75
Overvalued
PROFIT vs RISK RATING
1..100
10049
SMR RATING
1..100
9593
PRICE GROWTH RATING
1..100
4850
P/E GROWTH RATING
1..100
10011
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PCRX's Valuation (56) in the Pharmaceuticals Other industry is in the same range as TEVA (75) in the Pharmaceuticals Generic industry. This means that PCRX’s stock grew similarly to TEVA’s over the last 12 months.

TEVA's Profit vs Risk Rating (49) in the Pharmaceuticals Generic industry is somewhat better than the same rating for PCRX (100) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew somewhat faster than PCRX’s over the last 12 months.

TEVA's SMR Rating (93) in the Pharmaceuticals Generic industry is in the same range as PCRX (95) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew similarly to PCRX’s over the last 12 months.

PCRX's Price Growth Rating (48) in the Pharmaceuticals Other industry is in the same range as TEVA (50) in the Pharmaceuticals Generic industry. This means that PCRX’s stock grew similarly to TEVA’s over the last 12 months.

TEVA's P/E Growth Rating (11) in the Pharmaceuticals Generic industry is significantly better than the same rating for PCRX (100) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew significantly faster than PCRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PCRXTEVA
RSI
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
64%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
67%
Bullish Trend 3 days ago
68%
Momentum
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
73%
MACD
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
71%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
68%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
80%
Bullish Trend 3 days ago
68%
Advances
ODDS (%)
Bullish Trend 10 days ago
70%
Bullish Trend 6 days ago
72%
Declines
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
72%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
78%
Aroon
ODDS (%)
Bullish Trend 3 days ago
68%
Bullish Trend 3 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
PCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TEVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
JAVA68.560.49
+0.72%
JPMorgan Active Value ETF
OAKM26.970.18
+0.67%
Oakmark U.S. Large Cap ETF
GGUS62.700.33
+0.53%
Goldman Sachs MktBt Russell LgCpGrEqETF
BUFT24.130.04
+0.17%
FT Vest Buffered Allctn Dfnsv ETF
MVPL36.060.05
+0.14%
Miller Value Ptnrs Leverage ETF

PCRX and

Correlation & Price change

A.I.dvisor tells us that PCRX and ELAN have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PCRX and ELAN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PCRX
1D Price
Change %
PCRX100%
-1.60%
ELAN - PCRX
31%
Poorly correlated
+3.65%
ALKS - PCRX
31%
Poorly correlated
+2.80%
TEVA - PCRX
29%
Poorly correlated
-0.11%
ETON - PCRX
28%
Poorly correlated
+5.61%
COLL - PCRX
28%
Poorly correlated
-0.69%
More

TEVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, TEVA has been loosely correlated with AMRX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if TEVA jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TEVA
1D Price
Change %
TEVA100%
-0.11%
AMRX - TEVA
41%
Loosely correlated
+1.56%
VTRS - TEVA
32%
Poorly correlated
+0.32%
ELAN - TEVA
29%
Poorly correlated
+3.65%
OGI - TEVA
23%
Poorly correlated
-3.43%
NBIX - TEVA
23%
Poorly correlated
+0.79%
More